NASDAQ:CRSP CRISPR Therapeutics Q1 2026 Earnings Results & Report $45.75 +0.60 (+1.33%) Closing price 11/11/2026 04:00 PM EasternExtended Trading$45.64 -0.11 (-0.24%) As of 11/11/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. CRISPR Therapeutics missed analyst expectations on both earnings and revenue in its Q1 2026 results, released May 4, 2026. The company reported EPS of -$1.28 versus the -$1.2185 consensus estimate, while revenue of $1.46 million fell short of the $6.06 million estimate by $4.61 million. Revenue increased 68.6% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 4, 2026TimeBefore Market OpensConference Call4:00 PM ET CRISPR Therapeutics EPS ResultsActual EPS-$1.28Consensus EPS -$1.2185Beat/MissMissed by -$0.0615One Year Ago EPS-$1.58EPS Beat Rate4 of last 8 quartersCRISPR Therapeutics Revenue ResultsActual Revenue$1.46 millionExpected Revenue$6.06 millionBeat/MissMissed by -$4.61 millionYoY Revenue Growth+68.60%Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) CRISPR Therapeutics Q1 2026 Earnings FAQ Did CRISPR Therapeutics beat earnings estimates for Q1 2026? CRISPR Therapeutics (NASDAQ:CRSP) reported earnings of -$1.28 per share for Q1 2026, missing the consensus estimate of -$1.2185. The report was announced on Monday, May 4, 2026. What was CRISPR Therapeutics' revenue for Q1 2026? CRISPR Therapeutics reported revenue of $1.46 million for Q1 2026, against a consensus estimate of $6.06 million. CRISPR Therapeutics Earnings HeadlinesJ.P. Morgan Keeps Their Buy Rating on Crispr Therapeutics AG (CRSP)November 10 at 3:36 PM | theglobeandmail.comCrispr Therapeutics: The Recent 40% Drop In Short Interest Indicates Deteriorating Bearish SentimentNovember 10 at 3:36 PM | seekingalpha.comWatch This NowJensen Huang, the man who launched the AI boom, just called what Elon Musk is chasing "the final frontier of AI." Musk's track record includes PayPal, Tesla and SpaceX. Tim Bohen has put the details of what he calls Musk's Mission X into a brand-new masterclass, free to watch with no credit card required. Viewers also receive a free ticker tied to Mission X. | StocksToTrade (Ad)CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare ConferenceNovember 10 at 10:34 AM | finance.yahoo.comCRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare ConferenceNovember 10 at 8:30 AM | globenewswire.comCRISPR Therapeutics: I Love The Medical Breakthroughs, I Don't Love The Stock - Strong SellNovember 9 at 7:07 PM | seekingalpha.comSee More CRISPR Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CRISPR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CRISPR Therapeutics and other key companies, straight to your email. Email Address About CRISPR TherapeuticsCRISPR Therapeutics (NASDAQ:CRSP) is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval. The companies share responsibilities for developing and commercializing Casgevy in authorized markets. Beyond Casgevy, CRISPR Therapeutics is advancing research programs in areas including cancer, autoimmune disease and in vivo gene editing. The company is led by CEO Samarth Kulkarni.View CRISPR Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going AwayPowering Up the Moon: Redwire’s $40 Million NASA Award Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
